UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19
VANCOUVER, British Columbia & SURREY, England–(BUSINESS WIRE)–Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected.
- Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours
- Trial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo
- Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant
- No adverse events were recorded in the group
- Submission for Emergency Use in the UK and Canada for the treatment and prevention of COVID-19 is planned immediately
Find out more here
“And the people stayed home.
And read books and listened, and rested and exercised,
and made art and played games,
and learned new ways of being and were still.
And listened more deeply.
Some meditated, some prayed, some danced.
Some met their shadows.
And the people began to think differently.
And the people healed.
And, in the absence of people living in ignorant, dangerous, mindless and heartless ways the earth began to heal.
And when the danger passed, and the people joined together again,
they grieved their losses, and made new choices,
and dreamed new images,